|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Maryland Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MarylandLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Novavax, Inc.
| | | Phone: | (240) 268-2000 | Year Established: | 1987 | Employees: | 300 | Ticker: | NVAX | Exchange: | NASDAQ | Main Contact: | John J. Trizzino, CBO & CFO | | Other Contacts: | Russell P. "Rip" Wilson, Senior VP, Business Development
Novavax Management Timothy J. Hahn, Ph.D., Senior VP, Global Manufacturing Operations Louis F. Fries III, M.D., Senior VP & CMO Amy B. Fix, M.S.,
M.B.A., R.A.C., Senior VP, Regulatory Affairs John A. Herrmann III, Senior VP & General Counsel Sven Andréasson, Senior VP, Corporate Development Gregory M. Glenn, MD, President, R&D Stanley C. Erck, President & CEO
| | Company Description | Novavax is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide. Using innovative virus-like particle (VLP) and recombinant nanoparticle technology, as well as new and efficient manufacturing approaches, the company produces potent vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Novavax is committed to using its technology platforms to create geographic-specific vaccine solutions and is therefore involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India and LG Life Sciences of Korea. Together, these companies have worldwide commercialization capacity and the global reach to create real and lasting change in the biopharmaceutical field. | |
|
|
|
|
|